HIVR4P 2023, the 5th HIV Research for Prevention Conference, Lima, Peru, and virtually, 22-26 October 2023

HIVR4P 2023，第五届艾滋病毒预防研究会议，秘鲁利马，虚拟会议，2023 年 10 月 22-26 日

• 批准号: 10617933
• 负责人: Christopher C. Beyrer
• 金额: $ 140万
• 依托单位: IAS
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10617933
• 关键词: AIDS prevention; Address; Adherence; Adolescent and Young Adult; Affect; African; Applied Research; Area; Attention; Basic Science; Brazil; COVID-19; COVID-19 pandemic; COVID-19 vaccine; Calibration; Cities; Clinical Trials; Collaborations; Communities; Complex; Country; Dapivirine; Disparity; Drug user; Effectiveness; Emergency response; Epidemic; Epidemiology; Face; Financial Support; Formulation; Fostering; Goals; Government; HIV; HIV Infections; HIV vaccine; Hearing; Hybrids; Incidence; Indigenous; Individual; Infection; Injectable; Injecting drug user; Injections; International; Intervention; Knowledge; Latin American; Leadership; Learning; Light; Male Circumcision; Maps; Misinformation; Modality; Oral; Outcome; Overdose; Participant; Pathway interactions; Persons; Peru; Population; Populations at Risk; Prevention; Prevention Research; Prevention program; Prevention trial; Primary Prevention; Provider; Public Health; Reporting; Research; Research Personnel; Risk; Role; Rural; Science; Scientific Advances and Accomplishments; Scientist; System; Technology; Therapeutic; Time; Travel; Vaccine Research; Vaccines; Vaginal Ring; Woman; Work; Writing; community barrier; cost; design; disinformation; efficacy trial; girls; implementation science; innovation; low and middle-income countries; men; men who have sex with men; multidisciplinary; neutralizing antibody; new technology; next generation; novel; novel strategies; personalized approach; pre-exposure prophylaxis; prevent; programs; response; sex; small molecule; substance use; substance user; suburb; success; symposium; synergism; transgender; transmission process; uptake; vaccine hesitancy; virtual; willingness

Project Summary UNAIDS set ambitious prevention goals and targets for HIV incidence reductions for 2020. We were not on a trajectory for success for those goals before the COVID-19 pandemic, and are at risk of further expansion of HIV epidemics. Declines in surveillance capacity also threaten our ability to assess HIV epidemic trajectories in many settings of risk. We face daunting challenges of ongoing transmission, and of growing gaps and disparities in primary prevention. Yet the existing and expanding toolkit for biomedical prevention of HIV infection has never had as much diversity, and as many high efficacy options, as today. Adolescents and younger adults in African settings and in key populations globally continue to bear the greatest burdens of HIV incidence, and to have the greatest challenges using and benefitting from biomedical HIV prevention advances. This population will be at the center of HIVR4P 2023. A particular focus will also be made on people who inject drugs or who use substances in sexual settings and have been understudied and underserved in HIV prevention. In the field of HIV vaccines, the COVID-19 pandemic highlighted new threats in terms of vaccines hesitancy. It is time now to investigate and report on new ways to addressing hesitancy and to understanding barriers to the uptake of novel HIV vaccines, prevention technologies and approaches. HIVR4P 2023, the 5th HIV Research for Prevention Conference taking place from 22 to 26 October 2023 in Lima, Peru, will be an opportunity for the HIV prevention community to hear, debate and weigh new scientific evidence, and to assess the increasingly complex prevention landscape and the next generation of research questions, including those for HIV vaccines, and the interactions of vaccines with non-vaccine prevention modalities. Lima was chosen as the host city to highlight scientific excellence in prevention research in the Latin American region while also drawing attention to the spiraling vulnerabilities and epidemics in the region. To facilitate everyone’s access to the conference regardless of their ability or willingness to travel, and recognizing that potential obstacles - including access to COVID-19 vaccines - might prevent key stakeholders particularly from countries with a high burden of HIV from travelling internationally, HIVR4P 2023 will be a fully hybrid conference. It will connect the two audiences both in Lima, which will provide a compelling venue for HIVR4P 2023 as a leading center of HIV prevention science, and online via the virtual conference platform. Specific aims for HIVR4P 2023 are to: 1. Convene the world’s experts in HIV prevention and related fields to advance scientific knowledge, present new research findings, and enhance global scientific and community collaborations 2. Advance HIV prevention technologies and implementation approaches that are tailored to the needs of those most at risk including adolescents and young adults, men who have sex with men, people who use drugs, sex workers, and transgender people globally, and women and girls in high-burden settings 3. Refine HIV prevention research agendas to reflect identified opportunities and knowledge gaps, including: Next generation HIV vaccines and bNAbs; hesitancy and misinformation; smarter delivery systems for small molecules, including longer-acting PrEP, depo formulation and multi-purpose technologies 4. Assess the state of the art of HIV vaccine research in light of the remarkable success of the COVID-19 vaccine enterprise, including the role of non-vaccine interventions in the next generation of HIV vaccine efficacy trials. The scientific program will consist of five thematic areas: basic science; PrEP and ARV-based prevention; Vaccines and bNAbs clinical trials; other prevention modalities and cross-cutting issues; applied and implementation science. The scientific program is developed by a multi-disciplinary international Organizing Committee. Cross-cutting aspects will be highlighted in plenary talks that also connect the science with community and leadership perspectives. Additionally, bridging sessions are designed to cut across the different thematic areas to provide opportunities for multi-disciplinary, multi-perspective dialogues, often using interactive formats. The participation of young researchers, basic scientists and researchers in related fields will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to remote-access options. Key science from the conference will be disseminated and discussed in regional contexts following HIVR4P 2023.

项目概要 联合国艾滋病规划署制定了雄心勃勃的预防目标和 2020 年减少艾滋病毒发病率的具体目标。 在 COVID-19 大流行之前实现这些目标的成功轨迹，并且面临艾滋病毒进一步蔓延的风险 流行病。监测能力的下降也威胁到我们评估许多地区艾滋病毒流行轨迹的能力 风险设置。我们面临着持续传播以及日益扩大的差距和差异的严峻挑战 一级预防。然而，现有的和不断扩展的艾滋病毒感染生物医学预防工具包从未 与今天一样具有多样性和高效的选择。非洲的青少年和年轻人 全球范围内的环境和重点人群继续承受着艾滋病毒发病率的最大负担，并且 使用艾滋病毒生物医学预防进展并从中受益的最大挑战。这个人口将在 HIVR4P 2023 的中心。还将特别关注注射吸毒者或吸毒者 性行为中使用的物质，并且在艾滋病毒预防方面尚未得到充分研究和服务。在领域 HIV 疫苗、COVID-19 大流行凸显了疫苗犹豫方面的新威胁。现在是时候了 调查并报告解决犹豫和理解小说吸收障碍的新方法 HIV 疫苗、预防技术和方法。 HIVR4P 2023，第五届艾滋病毒预防研究会议于 2023 年 10 月 22 日至 26 日在 秘鲁利马将为艾滋病毒预防界提供一个聆听、辩论和权衡新科学知识的机会 证据，并评估日益复杂的预防形势和下一代研究 问题，包括艾滋病毒疫苗的问题，以及疫苗与非疫苗预防的相互作用 方式。利马被选为主办城市，以突出拉丁地区预防研究方面的科学卓越性 美洲地区，同时也提请人们注意该地区不断加剧的脆弱性和流行病。 方便每个人参加会议，无论其旅行能力或意愿如何，以及 认识到潜在的障碍 - 包括获得 COVID-19 疫苗 - 可能会阻碍关键利益相关者 HIVR4P 2023 将全面 混合会议。它将连接利马的两个观众，这将为 HIVR4P 2023 作为艾滋病毒预防科学的领先中心，通过虚拟会议平台在线进行。 HIVR4P 2023 的具体目标是： 1. 召集世界艾滋病毒预防及相关领域的专家来推进科学知识， 提出新的研究成果，并加强全球科学和社区合作 2. 推进适合人群需求的艾滋病毒预防技术和实施方法 风险最高的人群包括青少年和年轻人、男男性行为者、使用 全球范围内的毒品、性工作者和跨性别者，以及高负担环境中的妇女和女童 3. 完善艾滋病毒预防研究议程，以反映已确定的机会和知识差距，包括： 下一代 HIV 疫苗和 bNAb；犹豫不决和错误信息；更智能的小型配送系统 分子，包括长效 PrEP、depo 制剂和多用途技术 4. 根据 COVID-19 的巨大成功评估 HIV 疫苗研究的最新水平 疫苗企业，包括非疫苗干预措施在下一代艾滋病毒疫苗中的作用 功效试验。 科学计划将包括五个主题领域：基础科学；基于 PrEP 和 ARV 的预防； 疫苗和 bNAb 临床试验；其他预防方式和跨领域问题；应用和 实施科学。该科学计划由多学科国际组织制定 委员会。全体会议将强调跨领域的问题，这些问题也将科学与 社区和领导的观点。此外，桥接会议旨在跨越不同的领域 专题领域为多学科、多视角对话提供机会，通常采用互动方式 格式。青年研究人员、基础科学家和相关领域研究人员的参与 此外，还通过积极征求相关科学知识和提供具体财政支持来加强 远程访问选项。会议的关键科学将在区域内传播和讨论 HIVR4P 2023 之后的背景。